MX2022005256A - Inhibidores de cd73. - Google Patents

Inhibidores de cd73.

Info

Publication number
MX2022005256A
MX2022005256A MX2022005256A MX2022005256A MX2022005256A MX 2022005256 A MX2022005256 A MX 2022005256A MX 2022005256 A MX2022005256 A MX 2022005256A MX 2022005256 A MX2022005256 A MX 2022005256A MX 2022005256 A MX2022005256 A MX 2022005256A
Authority
MX
Mexico
Prior art keywords
inhibitors
compounds
compositions
infections
cancer
Prior art date
Application number
MX2022005256A
Other languages
English (en)
Inventor
John Eksterowicz
Daqing Sun
Liusheng Zhu
Hiroyuki Kawai
Xiaohui Du
Yosup Rew
Valeria R Fantin
Brian R Blank
Jared Moore
Qiuping Ye
Tatiana Zavorotinskaya
Kejia Wu
Johnny Pham
Chien-Hung Yeh
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2022005256A publication Critical patent/MX2022005256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Abstract

En la presente se describen inhibidores de CD73 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones en cuestión son útiles para el tratamiento de cánceres, infecciones y enfermedades neurodegenerativas.
MX2022005256A 2019-10-30 2020-10-29 Inhibidores de cd73. MX2022005256A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US202063088646P 2020-10-07 2020-10-07
PCT/US2020/057996 WO2021087136A1 (en) 2019-10-30 2020-10-29 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
MX2022005256A true MX2022005256A (es) 2022-08-25

Family

ID=75686256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005256A MX2022005256A (es) 2019-10-30 2020-10-29 Inhibidores de cd73.

Country Status (12)

Country Link
US (5) US20220411459A1 (es)
EP (1) EP4051688A4 (es)
JP (1) JP2023500483A (es)
KR (2) KR102653726B1 (es)
CN (2) CN114929721B (es)
AU (1) AU2020375914A1 (es)
BR (2) BR112022008365A2 (es)
CA (1) CA3159248A1 (es)
IL (2) IL292570B2 (es)
MX (1) MX2022005256A (es)
NZ (1) NZ788133A (es)
WO (1) WO2021087136A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
MX2020011542A (es) 2018-04-30 2020-11-24 Oric Pharmaceuticals Inc Inhibidores de cd73.
KR102653726B1 (ko) * 2019-10-30 2024-04-01 오릭 파마슈티칼스, 인크. Cd73 억제제
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024059609A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. Pharmaceutical forms of a cd73 inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US20090029949A1 (en) 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
ES2963759T3 (es) * 2016-01-08 2024-04-01 Arcus Biosciences Inc Moduladores de la 5'-nucleotidasa, ecto y su uso
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
US11058704B2 (en) 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
CN110402249A (zh) 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
MX2020011542A (es) 2018-04-30 2020-11-24 Oric Pharmaceuticals Inc Inhibidores de cd73.
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
WO2020257429A1 (en) 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
KR102653726B1 (ko) 2019-10-30 2024-04-01 오릭 파마슈티칼스, 인크. Cd73 억제제

Also Published As

Publication number Publication date
BR122023021184A2 (pt) 2024-02-27
KR102653726B1 (ko) 2024-04-01
KR20240042573A (ko) 2024-04-02
US20210130390A1 (en) 2021-05-06
US11028120B2 (en) 2021-06-08
CN116854758A (zh) 2023-10-10
CN114929721B (zh) 2023-07-18
WO2021087136A1 (en) 2021-05-06
NZ788133A (en) 2024-03-22
US20230131747A1 (en) 2023-04-27
IL308293A (en) 2024-01-01
US11130778B2 (en) 2021-09-28
CN114929721A (zh) 2022-08-19
BR112022008365A2 (pt) 2023-03-28
US20210214387A1 (en) 2021-07-15
IL292570B2 (en) 2024-04-01
TW202130353A (zh) 2021-08-16
US11530236B2 (en) 2022-12-20
US20220411459A1 (en) 2022-12-29
IL292570A (en) 2022-06-01
CA3159248A1 (en) 2021-05-06
US20210130389A1 (en) 2021-05-06
JP2023500483A (ja) 2023-01-06
EP4051688A1 (en) 2022-09-07
KR20220088786A (ko) 2022-06-28
IL292570B1 (en) 2023-12-01
AU2020375914A1 (en) 2022-06-02
EP4051688A4 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
MX2023002507A (es) Inhibidores de cd73.
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
NZ788133A (en) Cd73 inhibitors
PH12018501920A1 (en) Bromodomain inhibitors
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
EP3909597A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EP3868385A4 (en) GASTRIC CANCER TREATMENT COMPOSITION INCLUDING A SYT11 INHIBITOR AS AN ACTIVE INGREDIENT
AU2018320416A8 (en) Pyridylpyridone compounds
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
WO2018211324A8 (en) Prodrugs for the treatment of disease
PH12021550323A1 (en) Dendrimer formulations
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EP3782620A4 (en) PHARMACEUTICAL COMPOSITION WITH A DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR THE PREVENTION OR TREATMENT OF SOLID CANCER OR BLOOD CANCER
WO2019157225A3 (en) Certain chemical entities, compositions, and methods
WO2019136310A3 (en) Novel compounds for the treatment of neurodegenerative diseases
WO2018067638A3 (en) High mobility group b1 protein inhibitors
EA202092473A1 (ru) Ингибиторы cd73